Presidio Pharmaceuticals Obtains $21,827,981 Series D Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=522ba020-9c82-4a80-9545-d62512c5787e
Date
6/16/2014
Company Name
Presidio Pharmaceuticals
Mailing Address
1700 Owens Street San Francisco, CA 94158 USA
Company Description
Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
Website
http://www.presidiopharma.com
Transaction Type
Venture Equity
Transaction Amount
$21,827,981
Transaction Round
Series D
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
M&A Terms
Venture Investor